Medical Supplies

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

Global Liquid Biopsy Market Forecast Reveals a 15.2% CAGR Growth Through 2035 Amid Rising Demand for Non Invasive Cancer Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Radiology, Biotechnology, Pharmaceutical, Medical Supplies, Oncology, Health, Medical Devices, Genetics, Diagnosis, Liquid biopsy, Medicine, Biomarker, Research, DNA, Prevalence, Development, Cancer, Application, Medical imaging

The global liquid biopsy market is projected to expand significantly, exhibiting a robust compounded annual growth rate (CAGR) of 15.2% through the year 2035.

Key Points: 
  • The global liquid biopsy market is projected to expand significantly, exhibiting a robust compounded annual growth rate (CAGR) of 15.2% through the year 2035.
  • The report underlines key factors propelling market growth, including the increasing demand for early cancer detection and the surging inclination toward non invasive diagnostic methods.
  • Liquid biopsy is hailed as a transformative approach in this research domain, especially for its targets in non invasive cancer diagnosis, patient monitoring, and precision medicine.
  • North America holds a significant share of the liquid biopsy market, with numerous companies actively investing in research and development.

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Managed Care, General Health, Oncology, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Surgery, Biotechnology, Nursing, Medical Supplies, Practice Management, Health, Growth, Prevalence, Application, Molecular Modeling Database, Incidence, Patient, Ventilation, Hospital, Acute respiratory distress syndrome, GE HealthCare, Asthma, Medtronic, COPD, Nursing care plan, ICU, USD, Ageing, Medical device

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

Retrieved on: 
Monday, March 18, 2024
Medical Devices, Health, Pharmaceutical, Clinical Trials, Medical Supplies, Immunodeficiency, Conference, KRMD, PIDD, Therapy, Patient, Impact, Literature, Primary immunodeficiency, Medical device

The study, authored by KORU Medical, analyzed data from a large national specialty pharmacy, capturing drug receipts over 4.5 years for 3,787 US PIDD patients using KORU Medical FREEDOM60® and FreedomEdge® infusion systems for self-administered SCIg therapy.

Key Points: 
  • The study, authored by KORU Medical, analyzed data from a large national specialty pharmacy, capturing drug receipts over 4.5 years for 3,787 US PIDD patients using KORU Medical FREEDOM60® and FreedomEdge® infusion systems for self-administered SCIg therapy.
  • We believe it provides valuable insights into the effectiveness of KORU Medical’s Freedom Infusion System in promoting treatment compliance in large volume subcutaneous delivery.
  • “These findings highlight the positive impact of KORU Medical’s Freedom Infusion System on subcutaneous immunoglobulin therapy for patients with primary immunodeficiency disease," said Brent Rutland, Vice President, Medical Affairs at KORU Medical.
  • These results, with the KORU Freedom Infusion System, also demonstrate the company’s potential to support a broader range of developmental subcutaneous drug therapies.”

seqWell Launches First Assay-ready, 384-well Library Preparation Kit to Enable Ultra-high Throughput Plasmid and Synthetic Construct Sequencing

Retrieved on: 
Monday, March 18, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, Health Technology, Genetics, Entrepreneurship, Synthetic biology, NGS, Workflow, Plastic, Multimedia, Plasmid, DBTL

ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.

Key Points: 
  • ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.
  • View the full release here: https://www.businesswire.com/news/home/20240318055628/en/
    seqWell's ExpressPlex HT 384-well library prep kit is the first commercially available next-generation sequencing library preparation kit enabling multiplexing up to 6,144 samples in a pre-plated 384-well format.
  • (Graphic: Business Wire)
    “ExpressPlex HT was a natural step in broadening our portfolio of scalable, multiplex library preparation solutions,” said Jack Leonard, Chief Technology Officer at seqWell.
  • Massive multiplexing using 6,144 indices and a fully automated, 90-minute library preparation workflow enable 24-hour sample-to-answer turnaround for greater than 6,000 samples.

HD Nursing and WellnessMats Announce Strategic Partnership, Improving Comfort and Safety of Healthcare Professionals with Medical Grade Premium Standing Solutions

Retrieved on: 
Friday, March 15, 2024
Other Professional Services, Health, Consumer, Other Health, Professional Services, Practice Management, Physical Therapy, Managed Care, General Health, Hospitals, Fitness & Nutrition, Seniors, Nursing, Medical Supplies, RN, Organization, Longevity, Partnership, Doctor of Philosophy, Safety, Patient safety, P4, HD, FAAN, Fatigue

“As the leader in Premium Standing Solutions and recognized for exemplary performance throughout various industries, we are thrilled to now join forces with HD Nursing and P4 to leverage our extensive experience to enhance the occupational comfort of medical and healthcare professionals,” says Daniel Bouzide, founder and president, WellnessMats. “This is a timely opportunity for healthcare leaders in virtually every healthcare setting to rethink and prioritize the well-being of their workforces and advance initiatives for employee retention -- one step at a time.”

Key Points: 
  • HD Nursing , the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention and WellnessMats , the leader in Premium Standing Solutions, proudly announce a strategic partnership.
  • This collaboration inaugurates a new era of improved comfort, safety, fatigue and stress relief for healthcare professionals and personnel throughout hospital and health system enterprises.
  • “This initiative underscores our joint dedication to advancing patient safety and supporting healthcare professionals throughout the healthcare ecosystem,” says Dr. Amy Hester, PhD, RN, BC, FAAN, chairwoman and CEO, HD Nursing.
  • Their professional-grade construction ensures a lasting investment that contributes to a positive work environment, improving employee retention and overall well-being.

Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research

Retrieved on: 
Friday, March 15, 2024
Research, Medical Devices, Medical Supplies, Baby, Maternity, Genetics, Health Technology, Health, Consumer, Science, Quality control, SVP, Workflow, FACMG, NGS, Element, Database, Gene, Collection, RUO, Doctor of Philosophy

Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.

Key Points: 
  • Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.
  • “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn sequencing research and providing critical components necessary to be able to go from sample to result,” said Madhuri Hegde, PhD, FACMG, SVP and chief scientific officer, Revvity.
  • “We are accelerating the democratization of genomic sequencing by addressing the typical challenges faced by labs.”
    The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process.
  • The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants.

Jadex Inc. Recognized as U.S. Best-in-Class Employer by Gallagher

Retrieved on: 
Monday, March 18, 2024
Human Resources, Medical Supplies, Health, Packaging, Engineering, Chemicals, Plastics, Professional Services, Manufacturing, Inc., Benefit, Communication

Jadex Inc. was recognized for its comprehensive framework for strategically investing in benefits, compensation and employee communication to support the health, financial security and career growth of its employees at a sustainable cost structure.

Key Points: 
  • Jadex Inc. was recognized for its comprehensive framework for strategically investing in benefits, compensation and employee communication to support the health, financial security and career growth of its employees at a sustainable cost structure.
  • Designations like Gallagher’s Best-in-Class Employer help current and potential employees understand and appreciate an organization’s workplace culture and people strategy; important differentiators as employers compete for talent in today’s labor market.
  • This also allows us to continue to attract and keep the best talent,” said Jeremy Rikala, Chief Human Resources Officer at Jadex.
  • “In doing so, Jadex utilizes data, workforce feedback tools and clearly defined policies to provide competitive benefits and experiences that their employees value.”

Butterfly Network Announces Investor Day

Retrieved on: 
Friday, March 15, 2024
Software, Radiology, Medical Supplies, Health, Medical Devices, Health Technology, Technology, Semiconductor, Network, Butterfly network

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, will host its previously announced Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, will host its previously announced Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.
  • A live audio webcast of the event will be available beginning at approximately 12:00pm ET, and will be available on Butterfly’s Events & Presentations page on the investor relations website.
  • An audio replay of the event will be available following the event on Butterfly’s Events & Presentations page on the investor relations website.

InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
Medical Devices, Medical Supplies, Hospitals, Professional Services, Practice Management, Other Health, General Health, Health, Oncology, Other Professional Services, Annual report, Forecasting, Growth, Patient, Travel, Capital expenditure, Sale, Public expenditure, Form 10-K, Long-term care, Risk, Bank statement, Adjustment, History, Comprehensive income, Depreciation, GAAP, Marketing, NPWT, Pharmaceutical industry

Gross profit for the fourth quarter of 2023 of $16.7 million increased $1.2 million, or 8%, from $15.5 million for the fourth quarter of 2022.

Key Points: 
  • Gross profit for the fourth quarter of 2023 of $16.7 million increased $1.2 million, or 8%, from $15.5 million for the fourth quarter of 2022.
  • Selling and marketing expenses for the fourth quarter of 2023 were $3.7 million, representing an increase of $0.8 million, or 25%, as compared to the fourth quarter of 2022.
  • General and administrative (“G&A”) expenses for the fourth quarter of 2023 were $11.5 million, an increase of 3% from $11.2 million for the fourth quarter of 2022.
  • The Company will conduct a conference call for all interested investors on March 14, 2024, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.